Kymera Therapeutics, Inc.
KYMR
$43.87
$2.054.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -275.43M | -240.88M | -223.86M | -167.47M | -157.85M |
| Total Depreciation and Amortization | 8.11M | 7.96M | 7.37M | 6.28M | 5.19M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.82M | 43.84M | 45.95M | 45.05M | 44.21M |
| Change in Net Operating Assets | -30.50M | -44.98M | -23.97M | -8.53M | 2.33M |
| Cash from Operations | -251.01M | -234.06M | -194.50M | -124.67M | -106.13M |
| Capital Expenditure | -1.91M | -5.90M | -12.84M | -23.53M | -31.79M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.43M | -18.95M | -391.24M | -430.17M | -203.71M |
| Cash from Investing | 19.52M | -24.86M | -404.08M | -453.69M | -235.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.59M | -1.56M | -1.58M | -358.00K | -57.00K |
| Issuance of Common Stock | 529.62M | 285.28M | 638.79M | 608.38M | 356.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.36M | -28.36M | -28.36M | -- | -- |
| Cash from Financing | 499.67M | 255.35M | 608.85M | 608.02M | 356.90M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 268.18M | -3.56M | 10.27M | 29.66M | 15.27M |